MONTREAL, May 4 /CNW Telbec/ - Theratechnologies (TSX: TH) reports on a positive meeting with the Therapeutic Products Directorate (TPD) of Health Canada held on May 3, 2005, in Ottawa for its Phase III program for ThGRF (TH9507) in HIV-associated lipodystrophy. Following this meeting, the Company is now preparing a Phase III Clinical Trial Application (CTA), which will be submitted to the Canadian regulatory body in the coming weeks. The response from the TPD is expected within 30 days of receipt of this application. "We received the go ahead for our Phase III program from the Food and Drug Administration (FDA) in the United States in late March. Following this positive meeting with Health Canada, we foresee no major hurdles that would prevent us from proceeding with our program also in Canada," said Yves Rosconi, President and Chief Executive Officer of the Company. "All elements of our Phase III program are coming together as planned and we are on track to enrol the first patient by mid-year," Mr. Rosconi concluded. Attractive market opportunity HIV-associated lipodystrophy is a metabolic syndrome that afflicts a large percentage of HIV patients undergoing antiretroviral therapy. It is characterized by changes in distribution of adipose tissue (fat-containing tissue), dyslipidemia and glucose intolerance. The changes in fat distribution include visceral fat accumulation and/or the loss of subcutaneous fat, generally in the limbs and facial area. There is currently no approved treatment for HIV-associated lipodystrophy, and although some new HIV treatments have shown signs of improving metabolic components of the disease, the accumulation of visceral fat, and the related complications, remains an important unmet medical need. It is estimated that, among the 1.4 million HIV-positive patients in North America and Europe, some 200,000 suffer from HIV-associated lipodystrophy with excess visceral fat. The Company estimates that this could translate into a market of several hundred million dollars. About ThGRF ThGRF is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces the production and secretion of growth hormone in a specific, physiological, controlled and pulsatile fashion. This property makes it a strong candidate as a potential treatment for many diseases related to aging and obesity, as these conditions are characterized by a significant reduction in growth hormone secretion. About Theratechnologies Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company engaged in the discovery and development of therapeutic peptides in the field of endocrinology and metabolism. The Company uses proprietary discovery technologies to expand its product portfolio. The most advanced clinical program (Phase III) targets HIV-associated lipodystrophy. Other clinical programs target wasting associated with chronic disease and type 2 diabetes. This press release contains forward-looking statements regarding the clinical development of ThGRF and its future commercialization in the indications described above. Such statements inherently involve numerous risks and uncertainties, including the success and timely completion of clinical trials, the ability of the Company to take advantage of the business opportunities in the biopharmaceutical industry, the granting of the necessary authorizations, and the general economic conditions. The Company, however, is not obligated to update this information and does not intend to do so. Investors are cautioned against placing undue importance on forward-looking information contained herein and should consult the Company's 2004 Annual Report, which contains a more exhaustive analysis of risks and uncertainties connected to the businesses of the Company.
Theratechnologies reports on a positive meeting with Health Canada for its ThGRF Phase III program
Earlier from Theratechnologies
- PRESS CONFERENCE - Theratechnologies Inc. - Invitation to Media
- Theratechnologies: Financial results for the first quarter of 2005 and recent operating highlights
Later from Theratechnologies
- Theratechnologies: four scientific posters at the Endocrine Society Annual Meeting
- Theratechnologies closes the sale of its investment in Celmed BioSciences
- Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy
- Theratechnologies: Financial results for the second quarter and recent operating highlights
- European pharmaceutical executive joins the Board of Theratechnologies
Follow Theratechnologies into a list and get an email when it puts out news.
Follow Theratechnologies